Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CRUSH-TB: Short-course Regimens for Pulmonary Tuberculosis
NCT05766267Phase 3Active, not recruiting
- Sponsor
- Centers for Disease Control and Prevention
- Start
- Nov 2023
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 6
01
Overview
A Phase 3 trial of bedaquiline, moxifloxacin, rifabutin, delamanid in pulmonary tuberculosis (TB), sponsored by Centers for Disease Control and Prevention. Started Nov 2023; status: active, not recruiting.
02
Drugs
bedaquilinemoxifloxacinrifabutindelamanid
03
Conditions
pulmonary tuberculosis (TB)
Beyond the preview
Go deeper on NCT05766267.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05766267.